Fülöp Tamas, Larbi Anis, Hirokawa Katsuiku, Mocchegiani Eugenio, Lesourds Bruno, Castle Stephen, Wikby Anders, Franceschi Claudio, Pawelec Graham
Research Center on Aging, Immunology Program, Geriatric Division, Faculty of Medicine, University of Sherbrooke, Sherbrooke, Quebec, Canada.
Clin Interv Aging. 2007;2(1):33-54. doi: 10.2147/ciia.2007.2.1.33.
The primary role of the immune system is to protect the organism against pathogens, but age-associated alterations to immunity increase the susceptibility of the elderly to infectious disease. The exact nature of these changes is still controversial, but the use of screening procedures, such as the SENIEUR protocol to exclude underlying illness, helped to better characterize the changes actually related to physiological aging rather than pathology. It is generally agreed that the most marked changes occur in the cellular immune response reflecting profound alterations in T cells. Much of this is due to thymic involution as well as changes in the proportions of T cell subpopulations resulting from antigen exposure, and altered T cell activation pathways. However, a body of data indicates that innate immune responses, including the critical bridge between innate and adaptive immunity, and antigen presenting capacity are not completely resistant to senescence processes. The consequences of all these alterations are an increased incidence of infections, as well as possibly cancers, autoimmune disorders, and chronic inflammatory diseases. The leading question is what, if anything, can we do to prevent these deleterious changes without dangerously dysregulating the precarious balance of productive immunity versus immunopathology? There are many potential new therapeutic means now available to modulate immunosenescence and many others are expected to be available shortly. One main problem in applying these experimental therapies is ethical: there is a common feeling that as ageing is not a disease; the elderly are not sick and therefore do not require adventurous therapies with unpredictable side-effects in mostly frail individuals. Animal models are not helpful in this context. In this chapter we will first briefly review what we think we know about human immunosenescence and its consequences for the health status of elderly individuals. We will then discuss possible interventions that might one day become applicable in an appropriate ethical environment.
免疫系统的主要作用是保护机体抵御病原体,但与年龄相关的免疫改变会增加老年人对传染病的易感性。这些变化的确切性质仍存在争议,但使用筛查程序,如SENIEUR方案来排除潜在疾病,有助于更好地描述与生理衰老而非病理相关的实际变化。人们普遍认为,最显著的变化发生在反映T细胞深刻改变的细胞免疫反应中。这在很大程度上是由于胸腺退化以及抗原暴露导致的T细胞亚群比例变化,以及T细胞活化途径的改变。然而,大量数据表明,先天免疫反应,包括先天免疫与适应性免疫之间的关键桥梁以及抗原呈递能力,并非完全不受衰老过程的影响。所有这些改变的后果是感染发生率增加,以及可能出现癌症、自身免疫性疾病和慢性炎症性疾病。首要问题是,如果有的话,我们能做些什么来预防这些有害变化,同时又不会危险地破坏有效免疫与免疫病理之间不稳定的平衡?现在有许多潜在的新治疗方法可用于调节免疫衰老,预计不久还会有更多方法出现。应用这些实验性疗法的一个主要问题是伦理问题:人们普遍认为,由于衰老不是一种疾病;老年人没有生病,因此不需要在大多数体弱个体中使用具有不可预测副作用的冒险疗法。在这种情况下,动物模型并无帮助。在本章中,我们将首先简要回顾我们认为自己所了解的人类免疫衰老及其对老年人健康状况的影响。然后我们将讨论可能有一天会在适当的伦理环境中适用的干预措施。